Background: This study is an attempt to investigate the effect of nano-liposome containing voriconazole on voriconazole-resistant A. flavus strains on the one hand, and to consider the expression of cyp51A and MDR1genes, regarded as important genes involved in the development of resistance to triazoles before and after voriconazole and voriconazole-loaded nano-liposomes exert their effects, on ...

voriconazole is an antifungal triazole, approved for management of invasive fungal diseases in patients. it is absorbed during two hours and its serum levels will be above 90%, based on the underlying factors, when the drug is administered orally. voriconazole shows a propotional increase in an area under the plasma concentration-time curve (auc), with increasing dose. plasma protein binding of...

ABSTRACT Fungal infections of the central nervous system (CNS) usually present as subacute meningitis or intracranial space occupying lesion with mass effect on surrounding structures and consequent focal neurological deficits. Intracranial fungal granulomas are often misdiagnosed clinically and radiologically as neoplastic lesions.  Biopsy of the lesion is the only reliable technique to estab...

Patients with impaired immunity are at particular risk of infections with Candida albicans. Antifungal drugs such as azoles commonly used for candidiasis treatment, but drug resistance is one of the most common problems for public health. The aim of this study was to evaluate the expression of lanosterol 14-demethylase (ERG11) gene for three-drug combinations in C. albicans. Disk diffusion and ...

BACKGROUND Voriconazole is frequently used to treat fungal infections in solid organ transplant patients. Recently, there have been reports suggesting that prolonged voriconazole therapy may lead to periostitis. AIM Here we present two cases of voriconazole-induced periostitis in solid organ transplant patients. CASE PRESENTATION Voriconazole was given to two transplant patients-one with a ...

Purpose To determine in vitro release profiles, transcorneal permeation, and ocular injection characteristics of a voriconazole-containing thermogel suitable for injection into the subconjunctival space (SCS). Methods In vitro release rate of voriconazole (0.3% and 1.5%) from poly (DL-lactide-co-glycolide-b-ethylene glycol-b-DL-lactide-co-glycolide) (PLGA-PEG-PLGA) thermogel was determined fo...

Voriconazole is a broad-spectrum triazole antifungal agent and the first-choice therapy for invasive aspergillosis (IA) (1). Although voriconazole is generally well tolerated, anecdotal case reports have described unexpected severe adverse events related to voriconazole, such as hyponatremia, which potentially could result in death (2–4). We report a case of successful voriconazole treatment of...

Voriconazole is a first-line agent for the treatment of invasive pulmonary aspergillosis. Isolates with elevated voriconazole MICs are increasingly being seen, and the optimal treatment regimen is not defined. We investigated whether the combination of voriconazole with anidulafungin may be beneficial for the treatment of A. fumigatus strains with elevated voriconazole MICs. We used an in vitro...

An antagonistic effect of voriconazole on the fungicidal activity of sequential doses of amphotericin B has previously been demonstrated in Candida albicans strains susceptible to voriconazole. Because treatment failure and the need to switch to other antifungals are expected to occur more often in infections that are caused by resistant strains, it was of interest to study whether the antagoni...